Oculis Holding (OCS) AI Stock Analysis

• Market Cap: $1.54B
• Dividend Yield: N/A
• Average Volume (3M): 58.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: N/A
• EPS Growth: -25.15%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 57,169,476
• 10 Day Avg. Volume: 127,612
• 30 Day Avg. Volume: 58,014
• PEG Ratio: 0.60
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.27
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 2.24K
• Enterprise Value/Gross Profit: -78.41
• Enterprise Value/Ebitda: -11.85
• 1Y Price Target: $45.40
• Price Target Upside: 68.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -1.75
• Revenue Forecast (FY): $4.71M

• Rating: 53 Neutral
• Price Target: $27.00 ▲(0.30% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is primarily held back by persistent losses and cash burn with limited revenue visibility, partially offset by a strong, low-debt balance sheet. Technicals are mixed (longer-term support but weaker near-term momentum), and valuation support is limited due to negative earnings and no dividend.

Positive Factors

Balance Sheet Strength

Extremely low leverage and a substantially larger equity base provide durable financial flexibility and lower solvency risk. This balance-sheet strength supports multi-year clinical programs, reduces bankruptcy risk, and preserves optionality for partnering or staged investment through 2–6 months and beyond.

Extended Cash Runway

Material cash and a recent $210M financing extend runway into 2029, materially reducing near-term financing pressure. This funding buffer enables execution of planned registrational trials and readouts, lowering near-term dilution risk and supporting milestone-driven value creation.

Advancing Late-Stage Pipeline

Breakthrough Therapy designation plus large Phase 3 enrollment and multiple planned registrational trials materially de-risk development pathways. Multiple programs and indications increase the chance of clinical or regulatory success and create multiple long-term commercialization vectors.

Negative Factors

High Cash Burn

Sustained negative operating cash flow near -$60M annually reflects heavy R&D spending to support late-stage programs. Absent successful readouts or new financing, continued cash burn will erode resources and force financing decisions that could compromise strategic execution over the next 2–6 months.

Pre-commercial Revenue Profile

The company remains pre-commercial with negligible and inconsistent revenue while incurring large net losses. Lack of product revenue means future viability hinges on clinical success and external capital rather than cash flow from operations, leaving long-term revenue visibility limited.

Ongoing Reliance on Equity Financing

Maintaining an at-the-market equity program and mixed securities shelf signals structural dependence on public capital markets to fund development. If market conditions tighten, the company may face dilution or delayed programs, making financing execution a persistent strategic risk.

Oculis Holding Business Overview & Revenue Model

Company Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

How the Company Makes Money

Oculis generates revenue through the development and commercialization of its ophthalmic products. The primary revenue streams include sales of its proprietary drug formulations, licensing agreements with pharmaceutical companies, and collaborations with research institutions and healthcare providers. Oculis may also engage in partnerships that involve joint development of new therapies, which can result in milestone payments and royalties based on sales performance. Additionally, the company may receive funding through grants or investments aimed at supporting its research and development initiatives.

Oculis Holding Financial Statement Overview

Summary

Financial profile is mixed: the balance sheet is a clear strength (very low leverage and a larger equity base), but the income statement and cash flow show a pre-commercial company with minimal/zero revenue, sizable operating and net losses, and ongoing negative operating/free cash flow that implies continued reliance on external funding.

Income Statement

The income statement reflects a pre-commercial biotech profile with minimal and inconsistent revenue (2024 revenue of ~$0.7M, dropping back to $0 in 2025) and persistent, sizable operating losses (EBIT roughly -$79M in 2025 vs. -$73M in 2024). Net losses remain large (about -$95M in 2025), indicating a high cash burn business model with limited near-term earnings visibility. The key positive is that losses have not meaningfully worsened versus prior years, but profitability and revenue traction are still absent.

Balance Sheet

The balance sheet is a relative strength: leverage is very low in recent years (debt-to-equity ~0.012 in 2025 and ~0.016 in 2024), supported by a large equity base (equity ~$196M in 2025 vs. ~$73M in 2024). This provides financing flexibility and reduces solvency risk despite ongoing losses. The main weakness is weak shareholder returns driven by losses (return on equity is deeply negative in 2024–2025), and the business remains dependent on external funding over time.

Cash Flow

Cash generation is weak, with consistently negative operating cash flow (about -$62M in 2025 vs. -$47M in 2024) and negative free cash flow of a similar magnitude. Free cash flow broadly tracks net loss (around 1.0x), suggesting losses are largely cash-based rather than purely accounting-driven—typical for R&D-heavy biotech but still a risk. The positive is that free cash flow did not deteriorate dramatically year-over-year, but the ongoing burn implies continued reliance on capital raises or other financing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	686.00K	0.00	0.00	0.00
Gross Profit	0.00	-51.40M	0.00	0.00	0.00
EBITDA	-79.15M	-72.80M	-87.09M	-31.90M	-13.17M
Net Income	-94.51M	-85.78M	-88.80M	-38.70M	-18.55M
Balance Sheet
Total Assets	236.23M	120.35M	114.35M	37.06M	58.04M
Cash, Cash Equivalents and Short-Term Investments	213.25M	98.66M	91.65M	19.79M	46.28M
Total Debt	2.32M	1.18M	605.00K	123.08M	114.27M
Total Liabilities	39.94M	46.97M	20.63M	135.05M	119.00M
Stockholders Equity	196.29M	73.38M	93.73M	-97.99M	-60.95M
Cash Flow
Free Cash Flow	-62.51M	-47.73M	-53.89M	-28.62M	-13.85M
Operating Cash Flow	-62.22M	-47.50M	-53.84M	-25.07M	-13.82M
Investing Cash Flow	-59.38M	-17.56M	-54.21M	-3.55M	-28.00K
Financing Cash Flow	178.60M	54.03M	129.67M	1.71M	55.19M

Oculis Holding Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Positive. The current price of 26.92 is below the 20-day moving average (MA) of 28.05, above the 50-day MA of 26.87, and above the 200-day MA of 20.94, indicating a neutral trend. The MACD of -0.19 indicates Positive momentum. The RSI at 47.21 is Neutral, neither overbought nor oversold. The STOCH value of 26.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OCS.

Oculis Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	67 Neutral	$8.45B	-21.87	-58.74%	―	364.98%	-25.33%
SYRE	59 Neutral	$3.45B	-45.32	-29.44%	―	―	-123.65%
EYPT	54 Neutral	$1.16B	-5.61	-88.31%	―	-7.38%	-49.03%
OCS	53 Neutral	$1.54B	-8.77	-80.98%	―	―	-25.15%
SPRY	53 Neutral	$882.75M	-6.70	-100.29%	―	5459.66%	-59.70%
UPB	52 Neutral	$524.71M	-7.51	-28.71%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Oculis Holding Corporate Events

Oculis Files 2025 Financials and Renews $100 Million ATM Program

On March 4, 2026, Oculis Holding AG filed its 2025 IFRS consolidated and statutory financial statements, which received an unqualified audit opinion confirming a true and fair view under IFRS and Swiss law. The audit highlighted research and development spending and related accruals as a key focus area, underscoring the company’s heavy investment in external clinical programs and the importance of accurate estimation of product development costs.

Also on March 4, 2026, the company renewed its at-the-market equity offering program by entering an amended and restated sales agreement with Leerink Partners tied to a new Form F-3 registration statement. The move preserves Oculis’s ability to raise up to $100 million in incremental equity over time, enhancing financial flexibility to support ongoing R&D and potentially strengthening its funding position in competitive ophthalmology and biotech capital markets.

The most recent analyst rating on (OCS) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.

Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline

On March 3, 2026, Oculis reported its fourth-quarter and full-year 2025 results, highlighting a transformative year marked by clinical advances and a strengthened balance sheet. Cash, cash equivalents and short-term investments rose to $268.7 million as of December 31, 2025, following $210 million of equity financings, extending the company’s cash runway into 2029 despite a wider annual net loss of $119.1 million driven by expanded late-stage development.

Operationally, Oculis advanced three key programs: Privosegtor secured FDA Breakthrough Therapy designation in optic neuritis and initiated the first PIONEER registrational trial in Q4 2025; OCS-01 completed enrollment of more than 800 patients in two Phase 3 DIAMOND trials in diabetic macular edema with topline data expected in Q2 2026; and Licaminlimab entered the PREDICT-1 genotype-based registrational trial in dry eye disease with data expected in Q4 2026. These developments position Oculis for multiple near-term registrational milestones and reinforce its strategy to redefine standards of care across ophthalmology and neuro-ophthalmology, targeting a combined addressable market estimated at over $30 billion.

The most recent analyst rating on (OCS) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.